Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials

References

• World Health OrganizationAntimicrobial resistance2016 Available from: http://www.who.int/mediacentre/factsheets/fs194/enAccessed April 12, 2017
   Google Scholar
• Centers for Disease Control and PreventionAcinetobacter in healthcare settings2010 Available from: https://www.cdc.gov/HAI/organisms/acinetobacter.htmlAccessed April 12, 2017
   Google Scholar
• GöttigSGruberTMHigginsPGWachsmuthMSeifertHKempfVADetection of pan drug-resistant Acinetobacter baumannii in GermanyJ Antimicrob Chemother2014692578257924833751
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationTygacil [prescribing information]2016 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021821s039lbl.pdfAccessed April 12, 2017
   Google Scholar
• BouchillonSKHobanDJJohnsonBMJohnsonJLHsiungADowzickyMJIn vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (test program; 2004)Diagn Microbiol Infect Dis20055217317916105561
   PubMed Web of Science ®Google Scholar
• SeifertHStefanikDWisplinghoffHComparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolatesJ Antimicrob Chemother2006581099110016980293
   PubMed Web of Science ®Google Scholar
• ReinertRRLowDERossiFZhangXWattalCDowzickyMJAntimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecyclineJ Antimicrob Chemother2007601018102917855724
   PubMed Web of Science ®Google Scholar
• JonesRNFerraroMJRellerLBSchreckenbergerPCSwensonJMSaderHSMulticenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter sppJ Clin Microbiol20074522723017093026
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionAntibiotic Resistance Threats in the United States, 2013AtlantaCDC2013 Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdfAccessed October 2, 2017
   Google Scholar
• LemosEVde la HozFPEinarsonTRCarbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysisClin Microbiol Infect20142041642324131374
   PubMed Web of Science ®Google Scholar
• CurcioDFernandezFVergaraJVazquezWLunaCMLate onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecyclineJ Chemother200921586219297274
   PubMed Web of Science ®Google Scholar
• TekçeAYErbayAÇabadakHYağcıSKarabiberNŞenSPan-resistant Acinetobacter baumannii mediastinitis treated successfully with tigecycline: a case reportSurg Infect (Larchmt)20111214114321348768
   PubMed Web of Science ®Google Scholar
• De LucaMAngelinoGCalò CarducciFIMultidrug-resistant Acinetobacter baumannii infection in childrenBMJ Case Rep2011 pii:bcr0220113807
   Google Scholar
• MoonSYPeckKRChangHHClinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter sppMicrob Drug Resist20121856256622775562
   PubMed Web of Science ®Google Scholar
• LeeYTTsaoSMHsuehPRClinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infectionsEur J Clin Microbiol Infect Dis2013321211122023553594
   PubMed Web of Science ®Google Scholar
• Kanık-YüksekSTezerHOzkaya-ParlakayAMultidrug-resistant Acinetobacter baumannii bacteremia treated with tigecycline in two pediatric burn patientsPediatr Infect Dis J201534677
   PubMed Web of Science ®Google Scholar
• LiouBHLeeYTKuoSCLiuPYFungCPEfficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failureAntimicrob Agents Chemother2015593637364025824230
   PubMed Web of Science ®Google Scholar
• KwonSHAhnHLHanOYLaHOEfficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumanniiBiol Pharm Bull20143734034624583855
   PubMed Web of Science ®Google Scholar
• KhawcharoenpornTPruetpongpunNTiamsakPRutchanawechSMundyLMApisarnthanarakAColistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumoniaInt J Antimicrob Agents20144337838224613422
   PubMed Web of Science ®Google Scholar
• ChengAChuangYCSunHYExcess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational studyCrit Care Med2015431194120425793437
   PubMed Web of Science ®Google Scholar
• ChaariAPhamTMnifBColistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis studyIntensive Care Med2015412018201926264246
   PubMed Web of Science ®Google Scholar
• PrasadPSunJDannerRLNatansonCExcess deaths associated with tigecycline after approval based on noninferiority trialsClin Infect Dis2012541699170922467668
   PubMed Web of Science ®Google Scholar
• QvistNWarrenBLeister-TebbeHEfficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trialSurg Infect (Larchmt)20121310210922439781
   PubMed Web of Science ®Google Scholar
• MatthewsPAlpertMRahavGA randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionsBMC Infect Dis20121229723145952
   PubMed Web of Science ®Google Scholar
• VasilevKReshedkoGOrasanRA phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniaeJ Antimicrob Chemother200862i29i4018684704
   PubMed Web of Science ®Google Scholar
• LaufLOzsvarZMithaIPhase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitisDiagn Microbiol Infect Dis20147846948024439136
   PubMed Web of Science ®Google Scholar
• SacchidanandSPennRLEmbilJMEfficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trialInt J Infect Dis2005925126116099700
   PubMed Web of Science ®Google Scholar
• BreedtJTerasJGardovskisJSafety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonamAntimicrob Agents Chemother2005494658466616251309
   PubMed Web of Science ®Google Scholar
• OlivaMERekhaAYellinAA multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [study ID numbers: 3074A1–301-WW; ClinicalTrials.gov identifier: NCT0081744]BMC Infect Dis200558816236177
   PubMed Web of Science ®Google Scholar
• FominPBeuranMGradauskasATigecycline is efficacious in the treatment of complicated intra-abdominal infectionsInt J Surg20053354717462257
   PubMedGoogle Scholar
• ChenZWuJZhangYEfficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trialBMC Infect Dis20101021720663130
   PubMed Web of Science ®Google Scholar
• BergalloCJasovichATegliaOSafety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacinDiagn Microbiol Infect Dis200963526118990531
   PubMed Web of Science ®Google Scholar
• TanaseanuCMilutinovicSCalistruPIEfficacy and safety of tigecycline versus levofloxacin for community-acquired pneumoniaBMC Pulm Med200994419740418
   PubMedGoogle Scholar
• FlorescuIBeuranMDimovREfficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized studyJ Antimicrob Chemother200862i17i2818684703
   PubMed Web of Science ®Google Scholar
• FreireATMelnykVKimMJComparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumoniaDiagn Microbiol Infect Dis20106814015120846586
   PubMed Web of Science ®Google Scholar
• TowfighSPasternakJPoirierALeisterHBabinchakTA multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infectionsClin Microbiol Infect2010161274128120670293
   PubMed Web of Science ®Google Scholar
• FishbainJPelegAYTreatment of Acinetobacter infectionsClin Infect Dis201051798420504234
   PubMed Web of Science ®Google Scholar
• DoiYMurrayGLPelegAYAcinetobacter baumannii: evolution of antimicrobial resistance-treatment optionsSemin Respir Crit Care Med201536859825643273
   PubMed Web of Science ®Google Scholar
• KalilACMeterskyMLKlompasMManagement of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic SocietyClin Infect Dis201663e61e11127418577
   PubMed Web of Science ®Google Scholar
• RamirezJDartoisNGandjiniHYanJLKorth-BradleyJMcGovernPCRandomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumoniaAntimicrob Agents Chemother2013571756176223357775
   PubMed Web of Science ®Google Scholar
• VerdePECurcioDImbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysisClin Infect Dis20125547147222511552
   PubMed Web of Science ®Google Scholar
• PelegAYPotoskiBAReaRAcinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary reportJ Antimicrob Chemother20075912813117082201
   PubMed Web of Science ®Google Scholar
• ReidGEGrimSAAldezaCAJandaWMClarkNMRapid development of Acinetobacter baumannii resistance to tigecyclinePharmacotherapy2007271198120117655518
   PubMed Web of Science ®Google Scholar
• KarageorgopoulosDEKelesidisTKelesidisIFalagasMETigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidenceJ Antimicrob Chemother200862455518436554
   PubMed Web of Science ®Google Scholar
• GordonNCWarehamDWA review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecyclineJ Antimicrob Chemother20096377578019158109
   PubMed Web of Science ®Google Scholar
• PoulikakosPTansarliGSFalagasMECombination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic reviewEur J Clin Microbiol Infect Dis2014331675168524832022
   PubMed Web of Science ®Google Scholar
• KimWYMoonJYHuhJWComparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patientsPLoS One201611e015064226934182
   PubMed Web of Science ®Google Scholar